# Sermorelin Dosage in Research: Doses, Routes, and Study Context > Sermorelin dosage as documented in research: doses studied in children and older adults, routes administered, and reconstitution context. No human dosing advice. The doses, routes, and durations used in published research — reported in "studied at X in [population]" form, never as a recommendation. ## Before the details This page reports the **sermorelin dosage** figures that appear in published studies — what was given, to whom, by which route, for how long. It is a record, not a protocol: research-grade sermorelin is supplied for laboratory work, not as a medicine to self-administer, so there are no instructions here for a person to follow. Doses in studies were set per body weight (for example, micrograms per kilogram) or as fixed milligram amounts, almost always by subcutaneous (under-the-skin) injection. Read the numbers as data points from the literature, each tied to the study that used them. ## Doses Used in Sermorelin Research The pediatric efficacy work used 30 mcg/kg/day subcutaneously at bedtime in growth-hormone-deficient children, the regimen that raised first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. Aging research in older men used 0.5 mg and 1 mg subcutaneously twice daily for 14 days, where the higher dose restored GH and IGF-1 toward young-adult levels [2]. A long-term analog study had age-advanced men and women self-inject 10 mcg/kg nightly for 16 weeks [9]. Pharmacokinetic and diagnostic work used the intravenous route: in 30 healthy men, intravenous GHRH(1-29)NH2 elicited GH release at doses as low as 0.25 mcg/kg, with maximal release around 1-2 mcg/kg [3]. Historically, a single intravenous bolus (commonly about 1 mcg/kg) was used to test pituitary GH reserve. These are the figures the studies report; none is offered as guidance for use in a person. ## The diagnostic dose, historically Beyond therapy, GHRH(1-29) had a diagnostic life. A single intravenous bolus — commonly around 1 mcg/kg — was used historically as a GH stimulation test: give the secretagogue, then measure how much GH the pituitary can release, as a read on its reserve. The pharmacokinetic study that mapped the dose-response supports the logic, showing significant GH release from doses as low as 0.25 mcg/kg and a maximal response near 1-2 mcg/kg in healthy men [3]. This is a one-time provocative dose for measurement, not a treatment regimen, and it is included here only to show the full range of doses the literature recorded — diagnostic, pediatric-therapeutic, and adult-research — each tied to a different purpose. ## Routes studied Subcutaneous injection is the primary route across the efficacy and aging studies [1][2][9]. Intravenous dosing appears in the pharmacokinetic and diagnostic literature [3]. The intranasal route was tested historically but performed poorly — bioavailability was only about 3-5%, meaning the overwhelming majority of an intranasal dose never reached circulation [3]. That low mucosal absorption is the practical reason GHRH(1-29) was studied as an injection, and it tracks with the wider criticism that oral, sublingual, and troche "sermorelin" products are degraded before they can act. ## Reconstitution and stability context Sermorelin acetate is supplied as a lyophilized powder and reconstituted with sterile diluent; once in solution it is typically refrigerated, because aqueous peptide solutions are prone to degradation [3]. Compounded preparations are made under USP sterile-compounding standards. This is handling and stability context from the literature and compounding framework — it describes how the material behaves, not how anyone should dose it. ## Why these figures are written as "studied at X in [population]" Every dose on this page is framed the same way on purpose: a quantity, a route, and the population it was tested in — never "the recommended dose." That convention is not legal throat-clearing; it is the most accurate way to report what the studies contain. A figure like 30 mcg/kg/day means something in GH-deficient children with a height-velocity endpoint [1] and something quite different transplanted onto a healthy adult, where no equivalent controlled outcome exists. The same is true of the 0.5-1 mg twice-daily figure from a 14-day older-men study [2] and the 10 mcg/kg nightly figure from a 16-week analog study [9]. Reporting the population alongside the number is what keeps a dose a data point rather than an instruction — and it is why nothing here should be read as guidance for use in a person. ## The populations the doses were tested in Dose figures only mean something attached to who received them. The 30 mcg/kg/day regimen was studied in prepubertal growth-hormone-deficient children — a population with a defined deficiency and a clear endpoint (height velocity) [1]. The 0.5-1 mg twice-daily regimen was studied in healthy older men with age-related GH decline, over just 14 days [2]. The 10 mcg/kg nightly regimen was studied in age-advanced men and women across 16 weeks [9]. The intravenous microgram-per-kilogram doses came from pharmacokinetic and diagnostic studies in healthy adults [3]. None of these populations is "a healthy adult seeking anti-aging benefit," which is exactly the gap between the dosing literature and the way the compound is marketed — and why the body-composition page keeps the credible numbers tied to tesamorelin rather than borrowed for sermorelin [6]. ## Why dosing schedules varied Study durations ranged from 14 days in older men [2] to 16 weeks in the analog study [9] to a 20-week GHRH-analog cognition trial [6] to 12-24 months in pediatric work [1]. Because each study set its own dose, route, and timeline to answer its own question, the literature does not define a single fixed course. The practical takeaway is interpretive: outcomes were measured per study, and reading any one regimen as a general rule overreads the data. --- A transit-board reading of the sermorelin literature — the GHRH(1-29) findings routed line by line, each GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the stop where the long-term adult data run out left openly unserviced; no clinic at this board and nothing here dosed, dispensed, or sold.